Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2

Stephen R Plymate; Rupal S Bhatt; Steven P Balk

doi:10.1016/j.ccell.2015.01.008

Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2

Cancer Cell. 2015 Feb 9;27(2):158-9. doi: 10.1016/j.ccell.2015.01.008.

Authors

Stephen R Plymate¹, Rupal S Bhatt², Steven P Balk³

Affiliations

¹ Department of Medicine, University of Washington and GRECC-VAPSHCS, Seattle, WA 98104, USA.
² Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
³ Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: sbalk@bidmc.harvard.edu.

PMID: 25670076
DOI: 10.1016/j.ccell.2015.01.008

Abstract

GATA2 has been well-characterized as a critical pioneer transcription factor for androgen receptor (AR) in prostate cancer. In this issue of Cancer Cell, Vidal and colleagues identify increased GATA2 and its AR-independent transactivation of IGF2 as a mechanism that can mediate taxane resistance through activation of IGF1/insulin receptor signaling.

Publication types

Comment

MeSH terms

Animals
GATA2 Transcription Factor / genetics*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics*

Substances

GATA2 Transcription Factor
GATA2 protein, human